Login / Signup

The Impact of Weight Loss during Chemoradiotherapy for Unresectable Esophageal Cancer: Real-World Results.

Tzu-Ting HuangShang-Yu ChouYun-Hsuan LinShau-Hsuan LiYen-Hao ChenHung-I LuChien-Ming LoFu-Min FangYi-Chun ChiuYeh-Pin ChouYu-Ming Wang
Published in: Life (Basel, Switzerland) (2022)
Weight loss is a common phenomenon presented in unresectable esophageal cancer (EC) patients during their definitive chemoradiotherapy (dCRT) treatment course. This study explored the prognostic value of weight changes during dCRT in unresectable EC patients. From 2009 to 2017, 69 cT4b thoracic EC patients undergoing complete curative dCRT without baseline malnutrition were included. Clinical factors were analyzed via the Cox proportional hazards model and survival was analyzed by the Kaplan-Meier method. During dCRT, the median weight loss percentage was 5.51% (IQR = 2.77-8.85%), and the lowest body weight was reached at 35 days (IQR = 23-43 days). Median OS of these patients was 13.5 months. Both univariate and multivariate analysis demonstrated that weight loss ≤ 4% during dCRT was significantly associated with superior OS with a hazard ratio of 2.61 (95% CI: 1.40-4.85, p = 0.002). The median OS for patients with weight loss ≤ 4% and >4% during dCRT was 59.6 months and 9.7 months, respectively ( p = 0.001). Our study demonstrated that weight loss ≤ 4% during dCRT course is a favorable prognostic factor for cT4b EC patients. This index could serve as a nutrition support reference for unresectable EC patients receiving dCRT in the future.
Keyphrases